The Institute of Cancer Research (ICR), London and The Royal Marsden NHS Foundation Trust have announced the results of phase 1 trial research evaluating a drug combination targeting multiple mutant versions of cancer’s ‘death star’ protein.
The combination has provided promise in an early-phase clinical trial for patients diagnosed with advanced lung, ovarian and thyroid cancer and the research will be presented at the American Society of Clinical Oncology (ASCO) annual meeting.
